Tay’s License Agreement with VYNE Therapeutics

Pietro Martinoia Europe Legal Chronicle
Tagged:

Goodwin advised Tay on the agreement.Tay entered into a license agreement with VYNE Therapeutics, under which VYNE obtained exclusive rights to Tay’s oral BET inhibitor, TAY-B2 (VYN202)….

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Pietro Martinoia

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here